Skip to main content
SpringerLink
Log in
Book cover

Current Cancer Therapeutics pp 217–229Cite as

Sarcomas

  • Chapter

  • 133 Accesses

Abstract

Sarcomas are a histologically diverse group of tumors that arise most often from tissues of mesodermal origin. Despite the fact that approximately 75% of the body is derived from mesoderm, sarcomas are relatively rare, representing only 1% of all adult tumors and 15% of pediatric neoplasms. Approximately 6000 new cases of sarcoma are diagnosed each year, and half of these patients will eventually succumb to their disease. This chapter focuses on the current management of sarcomas arising in the soft tissue and bone in the adult population.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gaynor J, Tan C, Casper E, et al.: Refinement of clinicopathological staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Onco1 1992, 10:1317–1325.

    CAS  Google Scholar 

  2. Brennan MF, Casper ES, Harrison LB: Soft tissue sarcoma. In Principles and Practice of Oncology, edn 5. Edited by Rosenberg S, Devita V, Hellman S. Philadelphia: Lippincott-Raven ;1997:1738–1787.

    Google Scholar 

  3. Broders O, Hargrave R, Meyerding H: Pathological features of soft tissue fibrosarcomas with special reference to the grading of its malignancy. Surg Gynecol Obstet 1939, 69: 237–241.

    Google Scholar 

  4. American Joint Committee on Cancer: AJCC Cancer Staging Manual, edn 5. Edited by Fleming I, Cooper J, Heuson D,Philadelphia: Lippincott-Raven Publishers; 1997.

    Google Scholar 

  5. Barth R, Merino M, Solomon D, et al.: A prospective study of the value of core needle biopsy and fine needle aspiration in the diagnosis of soft tissue masses. Surgery 1992, 112: 536–543.

    PubMed  Google Scholar 

  6. Ball A, Fisher C, Pittan M, et al.: Diagnosis of soft tissues tumor by tru-cut biopsy. Br J Surg 1990, 77: 756–760.

    Article  PubMed  CAS  Google Scholar 

  7. Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF: Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Onco1 1997, 4:425–431.

    Google Scholar 

  8. Spiro IJ, Rosenberg AE, Springfield D, Suit H: Combined surgery and radiation therapy for limb preservation in soft tissue sarcoma of the extremity: the Massachusetts General Hospital experience. Cancer Investigation 1995, 13: 86–95.

    Article  PubMed  CAS  Google Scholar 

  9. Geer RJ, Woodruff J, Casper ES, Brennan MF: Management of small soft tissue sarcoma of the extremity in adults. Arch Surg 1992, 127: 1285.

    Article  PubMed  CAS  Google Scholar 

  10. Yang JC, Chang AE, Baker AR, et al.: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998, 16: 97–203.

    CAS  Google Scholar 

  11. Lindberg RD, Martin RG, Romsdahl MM, Barkley HT Jr.: Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer 1981, 47: 2391–2397.

    Article  PubMed  CAS  Google Scholar 

  12. Abbatucci JS, Boulier N, de Ranieri J, et al.: Local control and survival in soft tissue sarcomas of the limbs, trunk walls and head and neck: a study of 113 cases. IntJRadiat Oncol Biol Phys 1986, 12: 579–586.

    Article  CAS  Google Scholar 

  13. Karakousis CP, Emrich LJ, Rao U, Krishnamsetty RM: Feasibility of limb salvage and survival in soft tissue sarcomas. Cancer 1986, 57: 484–491.

    Article  PubMed  CAS  Google Scholar 

  14. Potter DA, Kinsella T, Glatstein E, et al.: High-grade soft tissue sarcomas of the extremities. Cancer 1986, 58: 190–205.

    Article  PubMed  CAS  Google Scholar 

  15. Pisters PW, Harrison LB, Leung DH, et al.: Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.JClin Oncol 1998, 14: 859–868.

    Google Scholar 

  16. Yang J, Chang A, Baker A, et al.: A randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998, 16: 197–203.

    PubMed  CAS  Google Scholar 

  17. Spiro IJ, Gebhardt MC, Jennings LC, et al.: Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Onco1 1997, 24:540–546.

    CAS  Google Scholar 

  18. Suit HD, Willett CG: Radiation therapy of sarcomas of the soft tissues. Cancer Treat Res 1991, 56: 61–74.

    Article  PubMed  CAS  Google Scholar 

  19. Suit HD, Mankin HJ, Wood WC, Proppe KH: Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. Cancer 1985, 55: 2659–2667.

    Article  PubMed  CAS  Google Scholar 

  20. Suit HD, Proppe KH, Mankin HJ, Wood WC: Preoperative radiation therapy for sarcoma of soft tissue. Cancer 1981, 47: 2269–2274.

    Article  PubMed  CAS  Google Scholar 

  21. Temple WJ, Temple CL, Arthur K, et al.: Prospective cohort study of neoadjuvant treatment in conservative surgery of soft tissue sarcomas. Ann Surg Onco1 1997, 4:586–590.

    Article  CAS  Google Scholar 

  22. Lindberg R, Martin R, Romsdahl M, et al.: Conservative surgery and radiation therapy for soft tissue sarcomas. In Management of Primary Bone and Soft Tissue Tumors. Chicago: Year Book Medical ; 1977: 289.

    Google Scholar 

  23. Borden EC, Amato DA, Edmonson JH, et al.: Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 1990, 66: 862–867.

    Article  PubMed  CAS  Google Scholar 

  24. Casper ES, Gaynor JJ, Hajdu SI, et al.: A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991, 68: 1221–1229.

    Article  PubMed  CAS  Google Scholar 

  25. Edmonson JH, Ryan LM, Blum RH, et al.: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Onco1 1993, 11:1269–1275.

    CAS  Google Scholar 

  26. Verweij J, van Oosterom AT, Somers R, et al.: Chemotherapy in the multidisciplinary approach to soft tissue sarcomas: EORTC Soft Tissue and Bone Sarcoma Group studies in perspective. Ann Oncol 1992, 3 (suppl 2): S75 - S80.

    Article  PubMed  Google Scholar 

  27. Mouridsen HT, Bastholt L, Somers R, et al.: Adriamycin versus epirubicin in advanced soft tissue sarcomas: a randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. EurJ Cancer Clin Oncol 1987, 23: 1477–1483.

    Article  CAS  Google Scholar 

  28. Stuart-Harris RC, Harper PG, Parsons CA, et al.: High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmaco1 1983, 11:69–72.

    CAS  Google Scholar 

  29. Stuart-Harris R, Harper PG, Kaye SB, Wiltshaw E: High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev 1983, 10 (suppl A): 163–164.

    Article  PubMed  Google Scholar 

  30. Bramwell VH, Mouridsen HT, Santoro A, et al.: Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. EurJCancer Clin Onco1 1987, 23:311–321.

    Article  CAS  Google Scholar 

  31. Antman KH, Elias AD: Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Onco11990, 17:7–15.

    Google Scholar 

  32. Bramwell VH, Mouridsen HT, Santoro A, et al.: Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. EurJCancer Clin Onco1 1987, 23:311–321.

    Article  CAS  Google Scholar 

  33. Antman KH, Elias AD: Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Onco1 1990, 17:7–15.

    Google Scholar 

  34. Elias AD, Eder JP, Shea T, et al.: High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Onco1 1990, 8:170–178.

    CAS  Google Scholar 

  35. Buesa JM, Mouridsen HT, van Oosterom AT, et al.: High-dose DTIC in advanced soft-tissue sarcomas in the adult: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991, 2: 307–309.

    PubMed  CAS  Google Scholar 

  36. Antman KH, Crowley J, Balcerzak S, et al.: An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Onco1 1993, 11:1276–1285.

    CAS  Google Scholar 

  37. Schoenfeld DA, Rosenbaum C, Horton J, et al.: A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 1982, 50: 2757–2762.

    Article  PubMed  CAS  Google Scholar 

  38. Borden EC, Amato DA, Rosenbaum C, et al.: Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Onco1 1987, 5:840–850.

    CAS  Google Scholar 

  39. Baker LH, Frank J, Fine G, et al.: Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial: a phase III Southwest Oncology Group Study (7613). J Clin Onco1 1987, 5:851–861.

    CAS  Google Scholar 

  40. Santoro A, Tursz T, Mouridsen H, et al.: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the EORTC Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995, 13: 1537–1545.

    PubMed  CAS  Google Scholar 

  41. Pinedo HM, Bramwell VH, Mouridsen HT, et al.: Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules: a study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer 1984, 53: 1825–1832.

    Article  PubMed  CAS  Google Scholar 

  42. Edmonson JH, Long HJ, Kvols LK, et al.: Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? Ann Oncol 1997, 8: 637–641.

    Article  PubMed  CAS  Google Scholar 

  43. Bokemeyer C, Franzke A, Hartmann JT, et al.: A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997, 80: 1221–1227.

    Article  PubMed  CAS  Google Scholar 

  44. Steward WP, Verweij J, Somers R, et al.: Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. J Cancer Res Clin Onco1 1991, 117(suppl 4): S 193-S 197.

    Google Scholar 

  45. Hicks LG, Balcerzak SP, Zalupski M: GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial: a Southwest Oncology Group study. Cancer Invest 1996, 14: 507–512.

    Article  PubMed  CAS  Google Scholar 

  46. Le Cesne A, Judson I, Crowther D, et al.: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000, 14: 2676–2684.

    Google Scholar 

  47. Jaffar Z, Blum RH, Rosen G, et al.: Ifosfamide 14:24 GM/M2: an outpatient study in sarcomas. Proc Annu Meet Am Soc Clin Onco1 1998, 17: 1968.

    Google Scholar 

  48. Verweij J, Lee SM, Rub W, et al.: Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000, 18: 2081–1086.

    PubMed  CAS  Google Scholar 

  49. Amodio A, Carpano S, Paoletti G, et al.: Phase II study of docetaxel in patients with advanced stage soft tissue sarcoma. Clinical Trials 1998, 149: 121–125.

    CAS  Google Scholar 

  50. Edmonson JH, Ebbert LP, Nascimento AG, et al.:Phase II study of docetaxel in advanced soft tissue sarcomas. Ami Clin Onco1 1996, 6:574–576.

    Article  Google Scholar 

  51. Balcerzak SP, Benedetti J, Weiss GR, et al.: A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas: a Southwest Oncology Group study. Cancer 1995, 76: 2248–2252.

    Article  PubMed  CAS  Google Scholar 

  52. Casper ES, Waltzman RJ, Schwartz GK, et al.: Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest 1998, 16: 442–446.

    Article  PubMed  CAS  Google Scholar 

  53. Merimsky O, Meller I, Flusser G, et al.: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000, 45: 177–181.

    Article  PubMed  CAS  Google Scholar 

  54. Amodio A, Carpano S, Manfredi C, et al.: Gemcitabine in advanced stage soft tissue sarcoma: a phase II study. Clin Ter (Italy) , 1999, 150: 17–20.

    CAS  Google Scholar 

  55. Bramwell VH, Eisenhauer EA, Blackstein M, et al.: Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Onco1 1995, 6:847–849.

    CAS  Google Scholar 

  56. Geer RJ, Woodruff J, Casper ES, et al.: Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg 1992, 127: 1285–1289.

    Article  PubMed  CAS  Google Scholar 

  57. Omura A, Blessinf J, Major F, et al.: A randomized trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1985, 3: 1240–1245.

    PubMed  CAS  Google Scholar 

  58. Antman K, Suit H, Amato D,Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. J Clin Onco11984, 2:601–608.

    Google Scholar 

  59. Lerner H, Amato D, Savlov E,Eastern Oncology Cooperative Group: a comparison of adjuvant doxorubicin and observation for patients with localized soft tissue sarcoma. J Clin Onco11987, 5:613–617.

    Google Scholar 

  60. Alvegard T, Sigurdsson H, Mouridsen H, et al.: Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol 1989, 7: 1504–1513.

    PubMed  CAS  Google Scholar 

  61. Gherlinzoni F, Bacci G, Picci P, et al.: A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations. J Clin Oncol 1986, 4: 552–558.

    PubMed  CAS  Google Scholar 

  62. Antman KH, Ryan LM, Borden EC, et al.: Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10-year results and review of the literature. In Adjuvant Therapy of Cancer VI. Edited by Salmon SE. Philadelphia: WB Saunders ; 1990: 529–543.

    Google Scholar 

  63. Benjamin RS, Terjanian TO, Fenoglio CJ, et al.: The importance of combination chemotherapy for adjuvant treatment of high risk patients with soft tissue sarcomas of the extremities. In Adjuvant Therapy of Cancer V. Edited by Salmon S. Orlando, FL: Grune and Stratton ; 1987: 735–744.

    Google Scholar 

  64. Eilber FR, Giuliano AE, Huth JF, Morton DL: Post operative adjuvant chemotherapy (adriamycin) in high grade extremity soft tissue sarcoma: a randomized prospective trial. In Adjuvant Therapy of Cancer V. Edited by Salmon S. Orlando, FL: Grune and Stratton; 1987: 719–726.

    Google Scholar 

  65. Edmonson JH, Fleming TR, Ivins JC, et al.: Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas. J Clin Onco1 1984 , 2:1390–1406.

    CAS  Google Scholar 

  66. Rosenberg SA, Tepper J, Glatstein E, et al.: Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer 1983, 52: 424–434.

    Article  PubMed  CAS  Google Scholar 

  67. Bramwell VH, Rousse J, Steward WP,Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-reduced local recurrence but no improvement in survival: a study of the European Organization for research and treatment of cancer, soft tissue and bone sarcoma group. J Clin Onco1 1994, 12:1137–1149.

    Google Scholar 

  68. Glenn J, Kinsella T, Glatstein E, et al.: A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk. Cancer 1985, 55: 1206–1214.

    Article  PubMed  CAS  Google Scholar 

  69. Chang AE, Kinsella T, Glatstein E, et al.: Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Onco1 1988, 6:1491–1500.

    CAS  Google Scholar 

  70. Ravaud A, Bui NB, Coindre JM, et al.: Adjuvant chemotherapy with Cyvadic in high risk soft tissue sarcoma: a randomized prospective trial. In Adjuvant Therapy of Cancer. Edited by Salmon S. Philadelphia: WB Saunders ; 1990: 556–566.

    Google Scholar 

  71. Frustaci S, Gherlinzoni F, De Paoli A,Maintenance of Efficacy of Adjuvant Chemotherapy (CT) in Soft Tissue Sarcoma (STS) of the Extremities Up-Date of a Randomized Trial. Proc ASCO 1999: 2108.

    Google Scholar 

  72. Sarcoma Meta-analysis Collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997, 350: 1647–1654.

    Article  Google Scholar 

  73. Zalupski M, Ryan JR, Hussein ME, Baker LH: Systemic adjuvant chemotherapy for soft tissue sarcomas of the extremities. Surg Oncol Clin North Am 1993, 2: 621–636.

    Google Scholar 

  74. Zalupski M, Ryan JR, Hussein ME: Defining the role of adjuvant chemotherapy for patients with soft tissue sarcoma of the extremities. In Adjuvant Therapy of Cancer VII. Edited by Salmon SE. Philadelphia: JB Lippincott ; 1993: 385–392.

    Google Scholar 

  75. Pezzi CM, Pollock RE, Evans HL, et al.: Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg 1990, 211: 476–481.

    Article  PubMed  CAS  Google Scholar 

  76. Casper ES, Gaynor JJ, Panicek DM, Harrison LB: Preoperative and postoperative adjuvant chemotherapy for adults with high grade soft tissue sarcoma. Cancer 1994, 73: 1644–1650.

    Article  PubMed  CAS  Google Scholar 

  77. Casper ES, Gaynor JJ, Panicek DM, Harrison LB: Preoperative and postoperative adjuvant chemotherapy for adults with high grade soft tissue sarcoma. Cancer 1994, 73: 1644–1650.

    Article  PubMed  CAS  Google Scholar 

  78. van Geel AN, Pastorino U, Jauch KW, et al.: Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer: Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 1996, 77: 675–682.

    Article  PubMed  Google Scholar 

  79. Casson AG, Putman JB, Natarajan G, et al.: Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer 1992, 69: 662–668.

    Article  PubMed  CAS  Google Scholar 

  80. Putnam JB Jr., Roth JA: Surgical treatment for pulmonary metastases from sarcoma. Hematology Oncology Clinics of North America 1995, 9: 869–887.

    Google Scholar 

  81. Van Geel AN: EORTC Soft Tissue and Bone Sarcoma Group: phase III randomized study of neoadjuvant high-dose DOX/IFF with or without G-CSF followed by metastasectomy vs metastasectomy alone for lung metastases in patients with soft tissue sarcoma, EORTC 62933.Eggermont ANVI, Schraffordt Koops H, Klausner JM,Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas. Semin Onco1 1997, 24:547–555

    Google Scholar 

  82. Singer S, Antman K, Corson J, Eberlein TJ: Long-term salvagability for patients with locally recurrent soft-tissue sarcomas. Arch Surg 1992, 127: 548–554.

    Article  PubMed  CAS  Google Scholar 

  83. Weiser MR, Downey RJ, Leung DH, et al.:. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. JAm Coll Surg 2000, 191: 184–190.

    Article  CAS  Google Scholar 

  84. Jaques DP, Coit DG, Hajdu SI, Brennan MF: Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg 1990, 212: 51–59.

    Article  PubMed  CAS  Google Scholar 

  85. Heslin MJ, Lewis JJ, Nadler E,Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Onco1 1997, 15:2832–2839.

    Google Scholar 

  86. Dalton RR, Donohue JH, Mucha P Jr, et al.: Management of retroperitoneal sarcomas. Surgery 1989, 106: 725–732 (discussion 732–733).

    Google Scholar 

  87. Kinsella TJ, Sindelar WF, Lack E,Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas. J Clin Onco1 1988, 6:18–25.

    Google Scholar 

  88. Farhood A, Hajdu S, Shiu M, Strong E: Soft tissue sarcomas of the head and neck in adults. Am J Surg 1990, 160: 365–369.

    Article  PubMed  CAS  Google Scholar 

  89. Mankin HJ, Lange TA, Spanier SS: The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg Am 1982, 64: 1121–1127.

    PubMed  CAS  Google Scholar 

  90. Malawer M, Link MP, Donaldson SS: Sarcomas of bone. In Principles and Practice of Oncology, edn 5. Edited by Rosenberg S, Devita V, Hellman S Philadelphia: Lippincott-Raven ; 1997: 1789–1852.

    Google Scholar 

  91. Link MP, Goorin AM, Miser AW, et al.: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. NEnglJMed 1986, 314: 1600–1606.

    Article  CAS  Google Scholar 

  92. Elber F, Guiliano A, Eckardt J,Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Onco1 1987, 5:21–26.

    Google Scholar 

  93. Mosende C, Gutierrez M, Caparros B, Rosen G: Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcoma. Cancer 1977, 40: 2779–2786.

    Article  PubMed  CAS  Google Scholar 

  94. Rosen G, Marcove RC, Huvos AG, et al.: Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Onco1 1983, 106(suppl):55–67.

    Article  Google Scholar 

  95. Rosen G, Nirenberg A: Neoadjuvant chemotherapy for osteogenic sarcoma: a five year follow-up (T-10) and preliminary report of new studies (T-12). Prog Clin Biol Res 1985, 201: 39–51.

    PubMed  CAS  Google Scholar 

  96. Rosen G: Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics 1985, 8: 659–664.

    PubMed  CAS  Google Scholar 

  97. Goorin A, Baker A, Gieser P, Ayala A, et al.: No evidence for improved event free survival (EFS) with presurgical chemotherapy (PRE) for nonmetastatic extremity osteogenic sarcoma (OGS): preliminary results of randomized Pediatric Oncology Group (POG) trial [abstract]. ProcAm Soc Clin Oncol 1995, 14: 444.

    Google Scholar 

  98. Meyers PA, Heller G, Healey J, et al.: Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J lin Onco1 1992, 10:5–15.

    CAS  Google Scholar 

  99. Glasser DB, Lane JM, Huvos AG, et al.: Survival, prognosis, and therapeutic response in osteogenic sarcoma: the Memorial Hospital experience. Cancer 1992, 69: 698–708.

    Article  PubMed  CAS  Google Scholar 

  100. Provisor AJ, Ettinger LJ, Nachman JB, et al.: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Onco1 1997, 15:76–84.

    CAS  Google Scholar 

  101. Winkler K, Beron G, Delling G, et al.: Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Onco1 1988, 6:329–337.

    CAS  Google Scholar 

  102. Beattie EJ, Harvey JC, Marcove R, Martini N: Results of multiple pulmonary resections for metastatic osteogenic sarcoma after two decades. J Surg Onco1 1991, 46:154–155.

    Google Scholar 

  103. Burk CD, Belasco JB, O’Neill JA, Jr., Lange B: Pulmonary metastases and bone sarcomas: surgical removal of lesions appearing after adjuvant chemotherapy. Clin Orthop 1991, 88–92.

    Google Scholar 

  104. Goorin AM, Delorey MJ, Lack EE, et al.: Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol 1984, 2: 425–431.

    PubMed  CAS  Google Scholar 

  105. Flye MW, Woltering G, Rosenberg SA: Aggressive pulmonary resection for metastatic osteogenic and soft tissue sarcomas. Ann Thorac Surg 1984, 37: 123–127.

    Article  PubMed  CAS  Google Scholar 

  106. Putnam JB, Jr., Roth JA, Wesley MN, et al.: Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors. Ann Thorac Surg 1983, 36: 516–523.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Ronald H. Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Herbert J. Zeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David L. Bartlett
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Blum, R.H., Zeh, H.J., Bartlett, D.L. (2001). Sarcomas. In: Current Cancer Therapeutics. Current Medicine Group, London. https://doi.org/10.1007/978-1-4613-1099-0_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1099-0_12

  • Publisher Name: Current Medicine Group, London

  • Print ISBN: 978-1-57340-176-0

  • Online ISBN: 978-1-4613-1099-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation